ERASCA INC (ERAS) Stock Price, Forecast & Analysis
NASDAQ:ERAS • US29479A1088
ERAS Key Statistics, Chart & Performance
The current stock price of ERAS is 13.66 USD. In the past month the price increased by 32.49%. In the past year, price increased by 897.08%.
ERAS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ERAS. When comparing the yearly performance of all stocks, ERAS is one of the better performing stocks in the market, outperforming 99.82% of all stocks.
ERAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERAS. ERAS has a great financial health rating, but its profitability evaluates not so good.
ERAS Financial Highlights
Over the last trailing twelve months ERAS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 45.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.37% | ||
| ROE | -36.7% | ||
| Debt/Equity | 0 |
ERAS Forecast & Estimates
17 analysts have analysed ERAS and the average price target is 10.51 USD. This implies a price decrease of -23.09% is expected in the next year compared to the current price of 13.66.
ERAS Ownership
ERAS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 410.174B | ||
| AMGN | AMGEN INC | 17.23 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.61 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.698B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ERAS
Company Profile
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Company Info
ERASCA INC
3115 Merryfield Row, Third Floor
San Diego CALIFORNIA US
Employees: 103
Phone: 18584656511
ERASCA INC / ERAS FAQ
Can you describe the business of ERASCA INC?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
What is the stock price of ERASCA INC today?
The current stock price of ERAS is 13.66 USD. The price increased by 0.66% in the last trading session.
Does ERAS stock pay dividends?
ERAS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ERAS stock?
ERAS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ERASCA INC (ERAS) based on its PE ratio?
ERASCA INC (ERAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
Can you provide the market cap for ERASCA INC?
ERASCA INC (ERAS) has a market capitalization of 4.23B USD. This makes ERAS a Mid Cap stock.
Can you provide the short interest for ERAS stock?
The outstanding short interest for ERASCA INC (ERAS) is 10.11% of its float.